Abstract
Human Epidermal Growth Factor Receptor 2 (HER2) fluorescence in situ hybridization (FISH)-positivity requires anti-HER2 therapy in breast cancer (BC). This study aimed to determine whether the expression of HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis of early HER2-positive BC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
